MedDataX Logo

Food Effect Study in Healthy Volunteers

NCT ID: NCT07254286

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-11

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A phase 1 open-label, randomized, crossover food effect and formulation assessment for icovamenib capsule in healthy volunteers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a phase 1, open-label, randomized, single dose, up to 7-way crossover study. It is planned to enroll 60 healthy male and female subjects. Subjects will be randomized to receive one of 5 sequences, with N=12 per sequence. Subjects will be dosed in a single residency period. This study is designed to evaluate the effect of meal time and fat content of food on the PK and safety of the icovamenib capsule and the icovamenib hydroxypropyl methylcellulose (HPMC) capsule formulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Healthy Volunteer Food Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a Phase 1, open-label, randomized, single dose, up to 7-way crossover study.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regimen A

A - icovamenib capsule 100mg in fasted state

Group Type EXPERIMENTAL

Icovamenib

Intervention Type DRUG

Investigational Product

Regimen B

B - icovamenib capsule 100mg in the fed state (0.5 h after initiation of low-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib

Intervention Type DRUG

Investigational Product

Regimen C

C - icovamenib capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib

Intervention Type DRUG

Investigational Product

Regimen D

D - icovamenib capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib

Intervention Type DRUG

Investigational Product

Regimen E

E - icovamenib capsule 100mg in the fed state (1 h after initiation of a high-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib

Intervention Type DRUG

Investigational Product

Regimen F

F - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a high-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib HPMC

Intervention Type DRUG

Investigational Product

Regimen G

G - icovamenib HPMC capsule 100mg in the fed state (1h after initiation of a high-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib HPMC

Intervention Type DRUG

Investigational Product

Regimen H

H - icovamenib HPMC capsule 100mg in the fed state (0.5 h after initiation of a low-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib HPMC

Intervention Type DRUG

Investigational Product

Regimen I

I - icovamenib HPMC capsule 100mg in the fed state (1 h after initiation of a low-fat breakfast)

Group Type EXPERIMENTAL

Icovamenib HPMC

Intervention Type DRUG

Investigational Product

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Icovamenib

Investigational Product

Intervention Type DRUG

Icovamenib HPMC

Investigational Product

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BMF-219 BMF-219 HPMC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Informed Consent and Compliance

1. Must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures.
2. Must be willing and able to comply with all study requirements. Baseline Characteristics
3. Healthy males or non-pregnant, non-lactating healthy females.
4. Body mass index (BMI) of 18.0 to 27.0 kg/m2 as measured at screening.
5. HbA1c ≤ 5.6%.
6. Fasting glucose ≤ 99 mg/dL.

Exclusion Criteria

Medical/Surgical History and Mental Health

1. Mean QTcF interval greater than 440 msec on triplicate ECGs. Use of prescription or over-the-counter (OTC) medications known to significantly prolong the QT or QTcF interval.
2. History of hypertension or untreated hypertension (systolic blood pressure (BP) \>140 mmHg and/or diastolic BP \>90 mmHg).
3. Known self or family history (first-degree relative) of multiple endocrine neoplasia Type 1.
4. History of stomach or intestinal surgery or resection (except appendectomy, hernia and/or cholecystectomy).

Diagnostic assessments.
5. Clinically significant abnormal clinical chemistry, hematology, coagulation or urinalysis as judged by the investigator.
6. History or evidence of hepatitis C virus (HCV), or hepatitis B virus (HBV) infection or human immunodeficiency virus (HIV) at screening.
7. Estimated creatinine clearance (CLcr) of \<90 mL/min.
8. AST, ALT or bilirubin \> ULN at screening.
9. Prior Study Participation.
10. Subjects who have received any IMP in a clinical research study within 5 half-lives or within 30 days prior to first dose.
11. Prior and Concomitant Medication.
12. Subjects who are taking, or have taken, any prescribed or OTC drug or herbal remedies (other than HRT/hormonal contraception and up to 4 g per day acetaminophen) in the 14 days before first study medication administration.
13. Currently dieting (formal weight loss program) and/or are currently using or have used within 2 months of screening any drugs for weight management.
14. Received prior menin inhibitor treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biomea Fusion Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Biomea Fusion Inc.

Role: STUDY_DIRECTOR

Biomea Fusion Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Quotient Sciences - Miami, Inc.

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COVALENT-121

Identifier Type: -

Identifier Source: org_study_id